|
Winship Cancer Institute Cancer Center Support Grant
|
2P30CA138292-09
|
$2,524,399
|
$50,488
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-09S1
|
$59,999
|
$1,200
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-09S2
|
$102,081
|
$2,042
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Unlocking Tumor Immunophenotype in Responders versus Non-Responders in Metastatic Uveal Melanoma Patients Receiving Immune Checkpoint Blockade
|
5R21CA208609-02
|
$174,000
|
$174,000
|
PATEL, SAPNA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Understanding G alpha q/11 localization and trafficking in uveal melanoma
|
1F31CA224803-01
|
$44,044
|
$44,044
|
Randolph, Clinita
|
THOMAS JEFFERSON UNIVERSITY
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$474,811
|
$9,496
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Translational Research in Cancer
|
3P30CA056036-18S1
|
$58,442
|
$584
|
KNUDSEN, KAREN
|
THOMAS JEFFERSON UNIVERSITY
|
|
Translational Research in Cancer
|
3P30CA056036-18S2
|
$117,000
|
$1,170
|
KNUDSEN, KAREN
|
THOMAS JEFFERSON UNIVERSITY
|
|
Translational Research in Cancer
|
3P30CA056036-18S3
|
$175,000
|
$1,750
|
KNUDSEN, KAREN
|
THOMAS JEFFERSON UNIVERSITY
|
|
Translational Research in Cancer
|
5P30CA056036-18
|
$2,807,751
|
$28,078
|
KNUDSEN, KAREN
|
THOMAS JEFFERSON UNIVERSITY
|
|
The Zambia AIDS Malignancies Diagnosis and Pathogenesis Program (ZAMDAPP)
|
1U54CA221204-01
|
$670,280
|
$328,437
|
WOOD, CHARLES
|
UNIVERSITY OF NEBRASKA LINCOLN
|
|
The GNAQ pathway as a therapeutic target in uveal melanoma
|
5R01CA142873-08
|
$306,698
|
$306,698
|
BASTIAN, BORIS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Structural Biology of GTPase Activating Proteins
|
ZIA BC 011419
|
$513,634
|
$513,634
|
Byrd, R. Andrew
|
CCR (NCI)
|
|
Stable Water Isotope Labeling for Imaging of Rapidly Proliferating Cells
|
ZIA BC 011777
|
$24,641
|
$246
|
Buxbaum, Nataliya
|
CCR (NCI)
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-31S1
|
$116,250
|
$2,325
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-31S2
|
$106,499
|
$2,130
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-31S3
|
$83,463
|
$1,669
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-31S4
|
$60,000
|
$1,200
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-31S5
|
$180,000
|
$3,600
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-31S6
|
$116,655
|
$2,333
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
5P30CA023100-31
|
$3,795,641
|
$75,913
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Signaling Mechanisms of EphrinB1 in Cell Adhesion, Migration and Invasion
|
ZIA BC 010958
|
$427,953
|
$42,795
|
Daar, Ira
|
CCR (NCI)
|
|
Role of Trk Receptors in the Development and Function of Non-neuronal Structures
|
ZIA BC 010391
|
$512,529
|
$25,626
|
Tessarollo, Lino
|
CCR (NCI)
|
|
Retinoblastoma family study
|
ZIA CP004410-08277
|
$7,548
|
$3,774
|
Tucker, Margaret
|
DCEG (NCI)
|
|
REGULATION OF UVEAL MELANOMA CELL FATE BY THE PKC PATHWAY VIA MITF
|
5R01CA193321-03
|
$362,569
|
$362,569
|
MITSIADES, NICHOLAS
|
BAYLOR COLLEGE OF MEDICINE
|
|
Regulation of Ciliogenesis and Ciliary-related signaling
|
ZIA BC 011398
|
$997,455
|
$49,873
|
Westlake, Christopher
|
CCR (NCI)
|
|
Proteomics of Metastatic and Non-Metastatic Uveal Melanoma
|
1R21CA209500-01A1
|
$206,843
|
$206,843
|
CRABB, JOHN
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
PHASE II SBIR CONTRACT - TOPIC 339 - MODULATION THERAPEUTICS - PD: DEEPA NARAYANAN - CO: ALEXIS HUDAK
|
261201700035C
|
$1,999,987
|
$1,999,987
|
UNKNOWN, UNKNOWN
|
MODULATION THERAPEUTICS, INC.
|
|
Noninvasive Contrast Enhanced Early Detection of Melanoma Liver Metastasis
|
2R42CA183376-02
|
$555,735
|
$555,735
|
YANG, JENNY
|
INLIGHTA BIOSCIENCES, LLC
|
|
Non-canonical WNT signaling in the invasion and metastasis of uveal melanoma
|
1F30CA217184-01
|
$33,744
|
$33,744
|
RICHARDS, JACKSON
|
UNIVERSITY OF UTAH
|
|
Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase Gene
|
ZIA BC 011038
|
$1,022,127
|
$51,106
|
Linehan, W. Marston
|
CCR (NCI)
|
|
Molecular Predictive Testing in Ocular Melanoma
|
2R01CA125970-11
|
$561,808
|
$561,808
|
HARBOUR, JAMES
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Molecular Mechanism and Therapy for Ocular Melanoma
|
1R01CA217642-01
|
$488,005
|
$488,005
|
ZHANG, KANG
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Molecular Genetics of Melanoma
|
5K24CA149202-08
|
$171,081
|
$56,457
|
TSAO, HENSIN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Mechanisms of Cross-talk Between EphrinB and Alternate Signaling Pathways
|
ZIA BC 010006
|
$427,953
|
$21,398
|
Daar, Ira
|
CCR (NCI)
|
|
Mechanisms of Action for KCN1 in the Control of Uveal Melanoma Metastasis
|
5R01CA176001-04
|
$323,700
|
$323,700
|
GROSSNIKLAUS, HANS
|
EMORY UNIVERSITY
|
|
Improving the Clinical Effectiveness and Understanding of the Biophysical Basis
|
5U19CA021239-38
|
$2,457,927
|
$245,793
|
HONG, THEODORE
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Immunotherapy Strategies for Uveal Melanoma
|
ZIA BC 010649
|
$294,260
|
$205,982
|
Kammula, Udai
|
CCR (NCI)
|
|
IMMUNOLOGICAL MODULATION OF OCULAR TUMOR METASTASES
|
5R01CA030276-35
|
$282,171
|
$282,171
|
NIEDERKORN, JERRY
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Identifying a nodal point for G alpha q signaling in eye disease
|
5R01CA202778-02
|
$340,838
|
$340,838
|
ODELBERG, SHANNON
|
UNIVERSITY OF UTAH
|
|
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium
|
5U54CA190163-04
|
$701,778
|
$14,036
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Genomics of multiple primary tumors
|
ZIA CP010131-10782
|
$214,814
|
$21,481
|
Morton, Lindsay
|
DCEG (NCI)
|
|
Genome-edited uveal melanoma cell lines for investigating constitutively active GNAQ and GNA11
|
5R03CA202316-02
|
$78,000
|
$78,000
|
WEDEGAERTNER, PHILIP
|
THOMAS JEFFERSON UNIVERSITY
|
|
Flow Cytometric Detection of Malignant Cells in Body Fluids
|
ZIC BC 011093
|
$168,285
|
$16,828
|
Stetler-Stevenson, Maryalice
|
CCR (NCI)
|
|
Families at high risk of cancer
|
ZIA CP004410-08285
|
$246,303
|
$22,167
|
Caporaso, Neil
|
DCEG (NCI)
|
|
DNA Repair in Human Cancer-Prone Genetic Diseases
|
ZIA BC 004517
|
$1,059,524
|
$211,905
|
Kraemer, Kenneth
|
CCR (NCI)
|
|
DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural
|
ZIA CP010144-10548
|
$1,414,523
|
$70,726
|
Stewart, Douglas
|
DCEG (NCI)
|
|
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA
|
5R01CA214146-02
|
$348,844
|
$348,844
|
GUTMANN, DAVID
|
WASHINGTON UNIVERSITY
|
|
Collecting multiple primary tumor tissues
|
ZIA CP010131-10719
|
$30,688
|
$3,069
|
Morton, Lindsay
|
DCEG (NCI)
|
|
Clinical Studies of the Molecular Genetic Basis of Kidney Cancer
|
ZIA BC 011028
|
$511,064
|
$25,553
|
Linehan, W. Marston
|
CCR (NCI)
|
Total relevant funding to Eye for this search: $8,571,228
|